Effect of dextromethorphan-quinidine on agitation in patients with Alzheimer disease dementia a randomized clinical trial

JAMA - Journal of the American Medical Association

Volumn 314, Issue 12, 2015, Pages 1242-1254

  Cummings, Jeffrey L ^a   Lyketsos, Constantine G ^b   Peskind, Elaine R ^c   Porsteinsson, Anton P ^d   Mintzer, Jacobo E ^e,f   Scharre, Douglas W ^g   De La Gandara, Jose E ^h   Agronin, Marc ⁱ   Davis, Charles S ^j   Nguyen, Uyen ^k   Shin, Paul ^k   Tariot, Pierre N ^l   Siffert, João ^k  

^a CLEVELAND CLINIC LOU RUVO CENTER FOR BRAIN HEALTH   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^e Roper St Francis Hospital   (United States)

^f RALPH H JOHNSON VA MEDICAL CENTER   (United States)

^g OHIO STATE UNIVERSITY   (United States)

^h Quantum Laboratories Inc   (United States)

ⁱ Miami Jewish Health Systems   (United States)

^j CSD Biostatistics   (United States)

^k AVANIR PHARMACEUTICALS   (United States)

^l BANNER ALZHEIMER S INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; CHOLINESTERASE INHIBITOR; DEXTROMETHORPHAN PLUS QUINIDINE; HYPNOTIC AGENT; LORAZEPAM; MEMANTINE; NEUROLEPTIC AGENT; NOOTROPIC AGENT; PLACEBO; DEXTROMETHORPHAN; DEXTROMETHORPHAN - QUINIDINE COMBINATION; DRUG COMBINATION; QUINIDINE;

ACUTE HEART INFARCTION; ADULT; AGED; AGGRESSION; AGITATION; ALZHEIMER DISEASE; ANEMIA; ARTICLE; BRADYCARDIA; CEREBROVASCULAR ACCIDENT; CLINICAL GLOBAL IMPRESSION SCALE; COGNITIVE DEFECT; COLON CANCER; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FALLING; FEMALE; FEMUR FRACTURE; HEMATURIA; HUMAN; KIDNEY INFECTION; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PSYCHOMOTOR DISORDER; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; THORAX PAIN; TREATMENT DURATION; URINARY TRACT INFECTION; CLINICAL TRIAL; COMPLICATION; DRUG COMBINATION; DRUG EFFECTS; MIDDLE AGED; PSYCHOMOTOR AGITATION; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AGGRESSION; ALZHEIMER DISEASE; DEXTROMETHORPHAN; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; PLACEBOS; PSYCHOMOTOR AGITATION; QUINIDINE; TREATMENT OUTCOME;

EID: 84942241583     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2015.10214     Document Type: Article

References (34)

1. Tractenberg RE, Weiner MF, Patterson MB, Teri L, Thal LJ. Comorbidity of psychopathological domains in community-dwelling persons with Alzheimer's disease. J Geriatr Psychiatry Neurol. 2003;16(2):94-99.
2. Ryu SH, Katona C, Rive B, Livingston G. Persistence of and changes in neuropsychiatric symptoms in Alzheimer disease over 6 months: the LASER-AD study. Am J Geriatr Psychiatry. 2005;13 (11):976-983.
3. Gilley DW, Bienias JL,Wilson RS, Bennett DA, Beck TL, Evans DA. Influence of behavioral symptoms on rates of institutionalization for persons with Alzheimer's disease. Psychol Med. 2004;34(6):1129-1135.
4. Rabins PV, Schwartz S, Black BS, et al. Predictors of progression to severe Alzheimer's disease in an incidence sample. Alzheimers Dement. 2013;9(2): 204-207.
5. Salzman C, Jeste DV, Meyer RE, et al. Elderly patients with dementia-related symptoms of severe agitation and aggression: consensus statement on treatment options, clinical trials methodology, and policy. J Clin Psychiatry. 2008; 69(6):889-898.
6. Kales HC, Gitlin LN, Lyketsos CG; Detroit Expert Panel on Assessment and Management of Neuropsychiatric Symptoms of Dementia. Management of neuropsychiatric symptoms of dementia in clinical settings: recommendations from a multidisciplinary expert panel. J AmGeriatr Soc. 2014;62(4):762-769.
7. Gitlin LN, Kales HC, Lyketsos CG. Nonpharmacologic management of behavioral symptoms in dementia. JAMA. 2012;308(19):2020- 2029.
8. Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia:meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry. 2006;14(3):191-210.
9. Porsteinsson AP, Drye LT, Pollock BG, et al; CitAD Research Group. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. JAMA. 2014;311(7):682-691.
10. Parsons CG, Quack G, Bresink I, et al. Comparison of the potency, kinetics and voltage-dependency of a series of uncompetitive NMDA receptor antagonists in vitro with anticonvulsive and motor impairment activity in vivo. Neuropharmacology. 1995;34(10):1239-1258.
11. Nguyen L, Robson MJ, Healy JR, Scandinaro AL, Matsumoto RR. Involvement of sigma-1 receptors in the antidepressant-like effects of dextromethorphan. PLoS One. 2014;9(2):e89985.
12. Codd EE, Shank RP, Schupsky JJ, Raffa RB. Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: structural determinants and role in antinociception. J Pharmacol Exp Ther. 1995;274(3):1263-1270.
13. Damaj MI, Flood P, Ho KK, May EL, Martin BR. Effect of dextrometorphan and dextrorphan on nicotine and neuronal nicotinic receptors: in vitro and in vivo selectivity. J Pharmacol Exp Ther. 2005; 312(2):780-785.
14. Pioro EP, Brooks BR, Cummings J, et al; Safety, Tolerability, and Efficacy Results Trial of AVP-923 in PBA Investigators. Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect. Ann Neurol. 2010;68(5):693-702.
15. Daly JP, Caplan JP. A naturalistic on-off-on trial of dextromethorphan/quinidine for agitation associated with cerebellar injury. Psychosomatics. 2012;53(5):470-473.
16. Fava M, Evins AE, Dorer DJ, Schoenfeld DA. The problem of the placebo response in clinical trials for psychiatric disorders: culprits, possible remedies, and a novel study design approach. Psychother Psychosom. 2003;72(3):115-127.
17. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3): 263-269.
18. Guy W. ECDEU Assessment Manual for Psychopharmacology (Revised). Rockville, MD: National Institute of Mental Health; 1976.
19. Fridericia LS. The duration of systole in an electrocardiogram in normal humans and in patients with heart disease. Ann Noninvasive Electrocardiol. 2003;8(4):343-351.
20. Herrmann N, Cappell J, Eryavec GM, Lanctôt KL. Changes in nursing burden following memantine for agitation and aggression in long-term care residents with moderate to severe Alzheimer's disease: an open-label pilot study. CNS Drugs. 2011;25(5):425-433.
21. Mintzer JE, Tune LE, Breder CD, et al. Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: a multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses. Am J Geriatr Psychiatry. 2007;15(11):918-931.
22. Herrmann N, Lanctôt KL, Rothenburg LS, Eryavec G. A placebo-controlled trial of valproate for agitation and aggression in Alzheimer's disease. Dement Geriatr Cogn Disord. 2007;23(2):116-119.
23. Chen YF, Yang Y, Hung HM,Wang SJ. Evaluation of performance of some enrichment designs dealing with high placebo response in psychiatric clinical trials. Contemp Clin Trials. 2011;32(4):592-604.
24. Doros G, Pencina M, Rybin D, Meisner A, Fava M. A repeated measures model for analysis of continuous outcomes in sequential parallel comparison design studies. Stat Med. 2013;32(16): 2767-2789.
25. Zellner A. An efficient method of estimating seemingly unrelated regressions and tests for aggregation bias. J AmStat Assoc. 1962;57(298): 348-368.
26. Tamura RN, Huang X. An examination of the efficiency of the sequential parallel design in psychiatric clinical trials. Clin Trials. 2007;4(4):309- 317.
27. Cummings J,Mintzer J, Brodaty H, et al. Agitation in cognitive disorders: International Psychogeriatric Association provisional consensus clinical and research definition. Int Psychogeriatr. 2015;27(1):7-17.
28. SotoM, Andrieu S, Nourhashemi F, et al. Medication development for agitation and aggression in Alzheimer disease: review and discussion of recent randomized clinical trial design. Int Psychogeriatr. 2015;27(2):181-197.
29. Lopez OL, Becker JT, Sweet RA, et al. Psychiatric symptoms vary with the severity of dementia in probable Alzheimer's disease. J Neuropsychiatry Clin Neurosci. 2003;15(3):346-353.
30. Brooks BR, Thisted RA, Appel SH, et al; AVP-923 ALS Study Group. Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: a randomized trial. Neurology. 2004;63(8):1364-1370.
31. Panitch HS, Thisted RA, Smith RA, et al; Pseudobulbar Affect in Multiple Sclerosis Study Group. Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis. Ann Neurol. 2006;59(5): 780-787.
32. Fox C, Crugel M, Maidment I, et al. Efficacy of memantine for agitation in Alzheimer's dementia: a randomised double-blind placebo controlled trial. PLoS One. 2012;7(5):e35185.
33. Trzepacz PT, Cummings J, Konechnik T, et al. Mibampator (LY451395) randomized clinical trial for agitation/aggression in Alzheimer's disease. Int Psychogeriatr. 2013;25(5):707-719.
34. Tariot PN, Schneider LS, Cummings J, et al; Alzheimer's Disease Cooperative Study Group. Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease. Arch Gen Psychiatry. 2011;68(8):853-861.